EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Vorinostat Improves Myotonic Dystrophy Type 1 Splicing Abnormalities in DM1 Muscle Cell Lines and Skeletal Muscle from a DM1 Mouse Model

Nafisa Neault iD, Aymeric Ravel-Chapuis iD, Stephen D Baird, John A Lunde, Mathieu Poirier, Emiliyan Staykov, Julio Plaza-Diaz iD, Gerardo Medina, Francisco Abadía-Molina iD, Bernard J Jasmin, Alex E MacKenzie iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24043794 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Nafisa Neault und 10 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 5B2, Canada. Hauptthemen laut MEDLINE: Myotonic Dystrophy, RNA Splicing, Vorinostat. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Ontario Genomics, AM from Genome Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myotonic dystrophy type 1 (DM1), the most common form of adult muscular dystrophy, is caused by an abnormal expansion of CTG repeats in the 3′ untranslated region of the dystrophia myotonica protein kinase (DMPK) gene. The expanded repeats of the DMPK mRNA form hairpin structures in vitro, which cause misregulation and/or sequestration of proteins including the splicing regulator muscleblind-like 1 (MBNL1). In turn, misregulation and sequestration of such proteins result in the aberrant alternative splicing of diverse mRNAs and underlie, at least in part, DM1 pathogenesis. It has been previously shown that disaggregating RNA foci repletes free MBNL1, rescues DM1 spliceopathy, and alleviates associated symptoms such as myotonia. Using an FDA-approved drug library, we have screened for a reduction of CUG foci in patient muscle cells and identified the HDAC inhibitor, vorinostat, as an inhibitor of foci formation; SERCA1 (sarcoplasmic/endoplasmic reticulum Ca2+-ATPase) spliceopathy was also improved by vorinostat treatment. Vorinostat treatment in a mouse model of DM1 (human skeletal actin–long repeat; HSALR) improved several spliceopathies, reduced muscle central nucleation, and restored chloride channel levels at the sarcolemma. Our in vitro and in vivo evidence showing amelioration of several DM1 disease markers marks vorinostat as a promising novel DM1 therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myotonic DystrophyRNA SplicingVorinostatAdultAnimalsHumansMiceAlternative SplicingMuscle CellsMuscle, SkeletalRNA, MessengerSarcoplasmic Reticulum Calcium-Transporting ATPasesTrinucleotide Repeat Expansion

Stichwörter der Autor:innen

myotonic dystrophy type 1new treatmentrare diseasesvorinostat

Substanzen

RNA, MessengerSarcoplasmic Reticulum Calcium-Transporting ATPasesVorinostat

Autor:innen und Institutionen

  • Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 5B2, Canada.
  • Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
  • Eric Poulin Center for Neuromuscular Disease, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
  • School of Pharmaceutical Sciences, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
  • Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18071 Granada, Spain.
  • Instituto de Investigación Biosanitaria IBS.GRANADA, Complejo Hospitalario Universitario de Granada, 18014 Granada, Spain.

ORCID-Profile: Nafisa Neault, Aymeric Ravel-Chapuis, Julio Plaza-Diaz, Francisco Abadía-Molina, Alex E MacKenzie

Förderung

  • CIHR
  • Ontario Genomics
  • AM from Genome Canada
  • Canadian Institutes of Health Research
  • Children’s Hospital of Eastern Ontario (CHEO) Foundation

Zitieren

APA

Neault, N., Ravel-Chapuis, A., Baird, S. D., Lunde, J. A., Poirier, M., Staykov, E., Plaza-Diaz, J., Medina, G., Abadía-Molina, F., Jasmin, B. J., & MacKenzie, A. E. (2023). Vorinostat Improves Myotonic Dystrophy Type 1 Splicing Abnormalities in DM1 Muscle Cell Lines and Skeletal Muscle from a DM1 Mouse Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043794

Vancouver

Neault N, Ravel-Chapuis A, Baird SD, Lunde JA, Poirier M, Staykov E, et al. Vorinostat Improves Myotonic Dystrophy Type 1 Splicing Abnormalities in DM1 Muscle Cell Lines and Skeletal Muscle from a DM1 Mouse Model. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043794

BibTeX
@article{Neault2023,
  author = {Neault, Nafisa and Ravel-Chapuis, Aymeric and Baird, Stephen D and Lunde, John A and Poirier, Mathieu and Staykov, Emiliyan and Plaza-Diaz, Julio and Medina, Gerardo and Abadía-Molina, Francisco and Jasmin, Bernard J and MacKenzie, Alex E},
  title = {Vorinostat Improves Myotonic Dystrophy Type 1 Splicing Abnormalities in DM1 Muscle Cell Lines and Skeletal Muscle from a DM1 Mouse Model},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24043794}
}
Kostenlos starten →